Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy